Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane

Gut

Volumn 47, Issue 6, 2000, Pages 812-819

  Kishimoto, Y ^a   Takata, N ^a   Jinnai, T ^a   Morisawa, T ^a   Shiota, G ^a   Kawasaki, H ^a   Hasegawa, J ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Aberrant crypt foci; Adenomatous polyposis coli; Azoxymethane; Colon; Cyclooxygenase; Non steroidal anti inflammatory drugs

Indexed keywords

AZOXYMETHANE; CARCINOGEN; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; MESSENGER RNA; SULINDAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON POLYPOSIS; CONTROLLED STUDY; GENE EXPRESSION; INTESTINE CRYPT; MALE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZOXYMETHANE; BLOTTING, NORTHERN; CARCINOGENS; COLON; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; ETODOLAC; GENE EXPRESSION; GENES, APC; INTESTINAL MUCOSA; ISOENZYMES; MALE; MEMBRANE PROTEINS; POLYMERASE CHAIN REACTION; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, INBRED F344; RNA, MESSENGER; SULINDAC;

EID: 0033671372     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.6.812     Document Type: Article

References (51)

1. Inhibition of prostaglandin synthesis as a mechanism of action of the aspirin-like drugs
2. Aberrant crypts: Potential preneoplastic lesions in the murine colon
3. Prevention by chemopreventive agents of azoxymethane-induced foci of aberrant crypts in rat colon
4. Use of azoxymethane-induced foci of aberrant crypts in rat colon to identify potential cancer chemopreventive agents
5. Suppression of azoxymethane-induced rat colon aberrant crypt foci by dietary protocatechuic acid
6. Chemoprevention of azoxymethane-induced colon carcinogenesis by dietary feeding of S-methyl methane thiosulfonate in male F344 rats
7. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats
8. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug during different stages of rat colon tumor development
9. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal antiinflammatory agent
10. Cyclooxygenase-1 and cyclooxygenase-2 gene expression in human colorectal adenocarcinomas and in azoxymethane induced colonic tumours in rats
11. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis
12. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2
13. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions
14. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: An in vitro study
15. Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane
16. Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats
17. β-Catenin is frequently mutated and demonstrates altered cellular location in azoxymethane-induced rat colon tumors
18. The interactions of APC, E-cadherin and β-catenin in tumour development and progression
19. Binding of GSK3β to the APC-β-catenin complex and regulation of complex assembly
20. Regulation of intracellular β-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein
21. Identification of c-MYC as a target of the APC pathway
22. PGH synthesis isozyme selectivity: The potential for safer nonsteroidal antiinflammatory drugs
23. COX-1 and COX-2. Toward the development of more selective NSAIDs
24. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1
25. The incidence of aberrant crypt foci and colonic carcinoma in dimethlhydrazine-treated rats varies in a site-specific manner and depends on tumor histology
26. Quantitative analysis of cyclooxygenase-2 gene expression on acute gastric injury induced by ischemia-reperfusion in rats
27. Competitive PCR for quantitation on mRNA
28. Determination of gene dosage by a quantitative adaptation of the polymerase chain reaction (gd-PCR): Rapid detection of deletions and duplications of gene sequences
29. Aspirin use and reduced risk of fatal colon cancer
30. Sulindac causes regression of rectal polyps in familial adenomatous polyposis
31. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas
32. Up-regulation of cyclooxygenase-2 gene expression in human colorectal adenomas and adenocarcinomas
33. Expression of prostaglandin G/H synthesis-1 and -2 protein in human colon cancer
34. Expression of cyclooxygenase-1 and -2 in human colorectal cancer
35. Suppression of intestinal polyposis in Apc716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)
36. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
37. Inhibition of NF-kappa B by sodium salicylate and aspirin
38. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
39. Peroxisome proliferator-activated receptors are activated by indomethacin and other non-steroidal anti-inflammatory drugs
40. NSAID effect on sporadic colon polyps
41. Effect of sulindac on sporadic colonic polyps
42. Localization of the gene for familial adenomatous polyposis on chromosome 5
43. Alteration of β-catenin expression in colonic epithelial cells of familial adenomatous polyposis patients
44. Expression of E-cadherin-associated molecules (α-, β- and γ-catenins and p120) in colorectal polyps
45. Activation of β-catenins-Tcf signaling in colon cancer by mutations in β-catenin or APC
46. Mutations of the Apc gene in experimental colorectal carcinogenesis induced by azoxymethane in F344 rats
47. Gastroscopic observation of the effect of aspirin and certain other substances on the stomach
48. Renal insufficiency associated with non-steroidal antiinflammatory agents
49. Differential inhibition of COX-1 and COX-2 in vitro and pharmacological profile in vivo of NSAIDs
50. Effects of nonsteroidal anti-inflammatory drugs on prostaglandins and renal function
51. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process